Search Results - "Choi, JaeDuk"

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial by Frias, Juan Pablo, Choi, JaeDuk, Rosenstock, Julio, Popescu, Luiza, Niemoeller, Elisabeth, Muehlen-Bartmer, Isabel, Baek, Seungjae

“…To assess the efficacy and safety of the glucagon-like peptide 1 receptor agonist (GLP-1 RA) efpeglenatide versus placebo in patients with type 2 diabetes…”
Get full text

FRI115 - A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects by Choi, JaeDuk, Kim, Youngmin, Eun, Kahee, Morrow, Linda, Hompesch, Marcus, Baek, Seungjae

Get full text

HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial by Abdelmalek, Manal, Choi, Jaeduk, Kim, Youngmin, Seo, Kyounghee, Hompesch, Marcus, Baek, Seungjae

Get full text

A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects by Choi, JaeDuk, Kim, Youngmin, Eun, Kahee, Morrow, Linda, Hompesch, Marcus, Baek, Seungjae

Get full text

LBP03 - HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial by Abdelmalek, Manal, Choi, Jaeduk, Kim, Youngmin, Seo, Kyounghee, Hompesch, Marcus, Baek, Seungjae

Get full text

A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis – Study design and rationale of HM-TRIA-201 study by Abdelmalek, Manal F., Suzuki, Ayako, Sanchez, Willian, Lawitz, Eric, Filozof, Claudia, Cho, Hyungjin, Baek, Eunhye, Choi, JaeDuk, Baek, Seungjae

“…Non-alcoholic steatohepatitis (NASH) is a multifactorial disease with an increasing prevalence worldwide due to the obesity pandemic. HM15211…”
Get full text

Cover Image, Volume 24, Issue 3 by Huh, Ki Young, Hwang, Jun Gi, Shin, Wonjung, BAEK, Seungjae, Choi, JaeDuk, Lee, Nora, Cho, Young Min, Lee, Howard

“…The cover image is based on the Original Article A double‐blind, placebo‐controlled, single‐ascending dose study to evaluate the safety, tolerability,…”
Get full text

A double‐blind, placebo‐controlled, single‐ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long‐acting glucagon analogue, in healthy subjects by Huh, Ki Young, Hwang, Jun Gi, Shin, Wonjung, BAEK, Seungjae, Choi, JaeDuk, Lee, Nora, Cho, Young Min, Lee, Howard

“…Aim To evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long‐acting glucagon analogue under development, in…”
Get full text

A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects by Jeon, Yoomin, Lee, Nora, Baek, Seungjae, Choi, JaeDuk, Jhee, Stanford, Lee, Howard

“…Background Eflapegrastim (Rolontis ® ) is a novel long‐acting pegylated recombinant human granulocyte colony-stimulating factor (G-CSF). Eflapegrastim has been…”
Get full text

Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials by Aroda, Vanita R., Frias, Juan Pablo, Ji, Linong, Niemoeller, Elisabeth, Nguyên‐Pascal, My‐Liên, Denkel, Karl, Espinasse, Melanie, Guo, Hailing, Baek, SeungJae, Choi, JaeDuk, Lingvay, Ildiko

“…Aim To evaluate the efficacy and safety of once‐weekly (QW) efpeglenatide in people with type 2 diabetes (T2D) suboptimally controlled with oral…”
Get full text

PSUN305 A Double-Blind, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136 in Obese or Overweight Subjects with Co-morbidities by Shin, Wonjung, Choi, JaeDuk, Yun, Hyori, Han, OakPil, Cho, Hyungjin, Hompesch, Marcus, Baek, Seungjae

“…Abstract HM15136 is a novel long-acting glucagon analogue with an extended half-life. In vivo efficacy studies of HM15136 in animal models showed its…”
Get full text